<html>
<head>
	<title>cbm20171102_8k.htm</title>
	<!-- Created by RDG HTML Converter v1.1.0.0 11/2/2017 11:22:55 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: Times New Roman,Times,serif; font-size: 10pt; margin-left: 10px; margin-right: 10px; cursor: auto;">
<p style="font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-indent: 61.5%; text-align: right;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Washington, D. C. 20549</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>FORM 8-K</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">CURRENT REPORT</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">Pursuant to Section 13 or 15(d) of</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">the Securities Exchange Act of 1934</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Date of Report (Date of earliest event reported) <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;</u><u>October 31</u><u>, 2017</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u> </u></font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Times New Roman,Times,serif; width: 100%;">

		<tr>
			<td style="width: 100%; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="margin: 0pt; text-align: center;">CA<font style="font-family:Times New Roman, Times, serif; font-size:10pt">MBREX CORPORATION</font></p>
			</td>
		</tr>
		<tr>
			<td style="text-align: center;">(Exact name of Registrant as specified in its charter)</td>
		</tr>

</table>

<p style="font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Times New Roman,Times,serif; width: 100%;">

		<tr>
			<td style="width: 33%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><font style="font-family:Times New Roman, Times, serif; font-size:10pt">DELAWARE</font></td>
			<td style="width: 33%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><font style="font-family:Times New Roman, Times, serif; font-size:10pt">1-10638</font></td>
			<td style="width: 33%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><font style="font-family:Times New Roman, Times, serif; font-size:10pt">22-2476135 </font></td>
		</tr>
		<tr>
			<td style="text-align: center;">(State or other jurisdiction</td>
			<td style="text-align: center;">(Commission File Number)</td>
			<td style="text-align: center;">(IRS Employer</td>
		</tr>
		<tr>
			<td style="text-align: center;">of incorporation)</td>
			<td>&nbsp;</td>
			<td style="text-align: center;">Identification No.)</td>
		</tr>

</table>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Times New Roman,Times,serif; width: 100%;">

		<tr>
			<td style="width: 85%; padding-left: 27pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><font style="font-family:Times New Roman, Times, serif; font-size:10pt">ONE MEADOWLANDS PLAZA, EAST RUTHERFORD, NEW JERSEY</font></td>
			<td style="width: 15%; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><font style="font-family:Times New Roman, Times, serif; font-size:10pt">07073</font></td>
		</tr>
		<tr>
			<td style="text-align: center; width: 85%;">(Address of principal executive offices)<font style="font-family:Times New Roman, Times, serif; font-size:10pt">&nbsp;&nbsp;</font></td>
			<td style="text-align: center; width: 15%;"><font style="font-family:Times New Roman, Times, serif; font-size:10pt">(Zip Code)</font></td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Registrant&#39;s telephone number, including area code:<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(201) 804-3000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Check the appropriate box if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2 below):</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">[ ] Pre-commencement communications pursuant to Rule 14d-2(d) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">(&sect;230.405 of this chapter) </font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">or Rule 12b-2 of the Securities Exchange Act of 1934 </font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">(&sect;240.12b-2 of this chapter)</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">.</font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">Emerging growth company [ ]</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="margin: 0pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CAMBREX CORPORATION</b></p>

<p>&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Form 8-K</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Current Report</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item 5.02 <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&ndash; Departure of Directors or </font></b><font style="font-family:Times New Roman, Times, serif;font-size:10pt;"><b>Certain</b><b> Officers; Election of Directors; Appointment of </b><b>Ce</b><b>rtain Officers; Compensatory Arrangements of Certain Officers.</b></font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">On <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">October 31, 2017, the Board of Directors of Cambrex Corporation appointed Dr. Gregory B. Brown, M.D. 64, as a member of the Company&rsquo;s Board of Directors for a term expiring on the date of its 2018 annual meeting. He will serve on the Audit and Regulatory Affairs Committees. Dr. Brown&rsquo;s appointment increases the size of the Board to 10 members.</font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In 2007, Dr. Brown co-founded HC Royalty Advisory Board, a healthcare-focused private asset management firm investing in biopharmaceutica<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">l and medical products. He has been the Vice Chairman of the Board of Directors and Chairman of the Strategic Advisory Board at HC Royalty since 2016, and has been involved in more than $1 billion of royalty financings. </font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Dr. <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">Brown currently serves as Chairman of the Board of Caladrius Biosciences, Inc., a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications. He is also a member of the Board and Audit Committee of Faron Pharmaceuticals, Oy, as well as a member of the Board, Audit, Governance and Product Selection Committees of MonoSol Rx, LLC, a specialty pharmaceutical company leveraging its proprietary PharmFilm technology to deliver drugs. Dr. Brown also serves on the Board of Vanderbilt Clinical S.a.r.l. He holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center and M.B.A. from Harvard Business School. </font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Dr. <font style="font-family:Times New Roman, Times, serif;font-size:10pt;">Brown will be paid </font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">in accordance with the Company&rsquo;s non-employee director compensation program, prorated for the current year, which is as follows: the compensation for non-employee directors consists of an annual retainer of $55,000 plus $5,000 annual retainer for each Committee he is a member of, and an annual award of such number of restricted stock units equivalent in value to $70,000 (determined by dividing $70,000 by the average of the highest and lowest trading prices of the Company&rsquo;s stock as reported on the NYSE on the date of the award) and an option to purchase $45,000 in value of shares of the Company&rsquo;s common stock (estimated on the date of the grant using the Black-Scholes option-pricing model based on the director&rsquo;s age and expected retirement date)</font><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">. </font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>Item 9.01 - Financial Statements and Exhibits</b></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">(d)<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp; &nbsp; Exhibits</font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: justify;"><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">(99.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Press release issued by Cambrex Corporation dated November 3, 2017.</font></p>

<p style="font-family: Times New Roman,Times,serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:center;">SIGNATURES</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:45pt;"><font style="font-family:Times New Roman, Times, serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on behalf by the undersigned hereunto duly authorized.</font></p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Times New Roman,Times,serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 50%;"><font style="font-family:Times New Roman, Times, serif; font-size:10pt">CAMBREX CORPORATION</font></td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Date: <font style="font-family:Times New Roman, Times, serif; font-size:10pt"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>November 3</u><u>, 2017</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>&nbsp;</font></td>
			<td><font style="font-family:Times New Roman, Times, serif; font-size:10pt">By:<u>&nbsp;&nbsp;&nbsp;/s/ </u><u>Samantha Hanley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></font></td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td><font style="font-family:Times New Roman, Times, serif; font-size:10pt">Name:&nbsp;&nbsp;&nbsp; Samantha Hanley</font></td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td><font style="font-family:Times New Roman, Times, serif; font-size:10pt">Title:&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Vice President</font></td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Exhibit 99.1<font style="font-family:Times New Roman, Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href="ex_98738.htm" style="-sec-extract:exhibit;">Press release dated November 3, 2017.</a></font></p>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "cbm20171102_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 17950}]
{"company-data": {"conformed-name": "CAMBREX CORP", "cik": "0000820081", "assigned-sic": "2834", "irs-number": "222476135", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-10638", "film-number": "171174683"}, "business-address": {"street1": "ONE MEADOWLANDS PLZ", "city": "E RUTHERFORD", "state": "NJ", "zip": "07073", "phone": "2018043000"}, "mail-address": {"street1": "ONE MEADOWLANDS PLAZA", "city": "E. RUTHERFORD", "state": "NJ", "zip": "07073"}}
cbm20171102_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
October 31
, 2017
CA
MBREX CORPORATION
(Exact name of Registrant as specified in its charter)
DELAWARE
1-10638
22-2476135
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of incorporation)
Identification No.)
ONE MEADOWLANDS PLAZA, EAST RUTHERFORD, NEW JERSEY
07073
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(201) 804-3000
Check the appropriate box if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2 below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(d) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter)
.
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
CAMBREX CORPORATION
Form 8-K
Current Report
Item 5.02
– Departure of Directors or
Certain
Officers; Election of Directors; Appointment of
Ce
rtain Officers; Compensatory Arrangements of Certain Officers.
On
October 31, 2017, the Board of Directors of Cambrex Corporation appointed Dr. Gregory B. Brown, M.D. 64, as a member of the Company's Board of Directors for a term expiring on the date of its 2018 annual meeting. He will serve on the Audit and Regulatory Affairs Committees. Dr. Brown's appointment increases the size of the Board to 10 members.
In 2007, Dr. Brown co-founded HC Royalty Advisory Board, a healthcare-focused private asset management firm investing in biopharmaceutica
l and medical products. He has been the Vice Chairman of the Board of Directors and Chairman of the Strategic Advisory Board at HC Royalty since 2016, and has been involved in more than $1 billion of royalty financings.
Dr.
Brown currently serves as Chairman of the Board of Caladrius Biosciences, Inc., a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications. He is also a member of the Board and Audit Committee of Faron Pharmaceuticals, Oy, as well as a member of the Board, Audit, Governance and Product Selection Committees of MonoSol Rx, LLC, a specialty pharmaceutical company leveraging its proprietary PharmFilm technology to deliver drugs. Dr. Brown also serves on the Board of Vanderbilt Clinical S.a.r.l. He holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center and M.B.A. from Harvard Business School.
Dr.
Brown will be paid
in accordance with the Company's non-employee director compensation program, prorated for the current year, which is as follows: the compensation for non-employee directors consists of an annual retainer of $55,000 plus $5,000 annual retainer for each Committee he is a member of, and an annual award of such number of restricted stock units equivalent in value to $70,000 (determined by dividing $70,000 by the average of the highest and lowest trading prices of the Company's stock as reported on the NYSE on the date of the award) and an option to purchase $45,000 in value of shares of the Company's common stock (estimated on the date of the grant using the Black-Scholes option-pricing model based on the director's age and expected retirement date)
.
Item 9.01 - Financial Statements and Exhibits
(d)
Exhibits
(99.1)            Press release issued by Cambrex Corporation dated November 3, 2017.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on behalf by the undersigned hereunto duly authorized.
CAMBREX CORPORATION
Date:
November 3
, 2017
By:
/s/
Samantha Hanley
Name:    Samantha Hanley
Title:       Vice President
Exhibit 99.1
Press release dated November 3, 2017.